model,flat_path,key_cat,val_cat,ref_val,pred_val,val_match,sim,score_status,piece,norm_path,from_pred,in_ref,in_pred,type_mismatch,is_enum,sim_failed
Claude-4.5-Sonnet,protocolSection.identificationModule.nctId,TP,TP,NCT03959423,NCT03959423,True,1.0,exact,NCTId,protocolSection.identificationModule.nctId,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.orgStudyIdInfo.type,EV,EV,,,,,,OrgStudyIdType,protocolSection.identificationModule.orgStudyIdInfo.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.orgStudyIdInfo.link,EV,EV,,,,,,OrgStudyIdLink,protocolSection.identificationModule.orgStudyIdInfo.link,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.briefTitle,TP,TP,Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System,Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects,True,0.96,success,BriefTitle,protocolSection.identificationModule.briefTitle,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.officialTitle,TP,TP,Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects,Safety Evaluation of the MiniMed AHCL System in Type 1 Adult and Pediatric Subjects,True,0.98,success,OfficialTitle,protocolSection.identificationModule.officialTitle,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.acronym,EV,EV,,,,,,Acronym,protocolSection.identificationModule.acronym,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.descriptionModule.briefSummary,TP,TP,This study is a Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects.,"This multicenter, single-arm study assessed the safety and effectiveness of an advanced hybrid closed-loop (AHCL) system with automated basal insulin delivery (Auto Basal) and automated bolus correction (Auto Correction) in 157 individuals with type 1 diabetes (T1D), including 39 adolescents (aged 14-21 years) and 118 adults (aged 22-75 years). After a run-in period using sensor-augmented pump therapy with or without predictive low glucose management or Auto Basal for approximately 14 days, participants used the AHCL system for approximately 90 days with glucose targets of 100 or 120 mg/dL. The study evaluated safety events and changes in A1C, time in range (TIR, 70-180 mg/dL), and time below range (TBR, <70 mg/dL).",True,0.84,success,BriefSummary,protocolSection.descriptionModule.briefSummary,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.descriptionModule.detailedDescription,TP,TP,"The purpose of this study is to evaluate the safety of the Advanced Hybrid Closed Loop system (AHCL) in type 1 diabetes adult and pediatric subjects in a home setting. The main objective in conducting this research is to collect data from patients who use the AHCL system at home, at work, at school and everywhere else. Subjects will use 670G 4.0 system with Guardian Sensor 3 (GS3) during study period, and will be allowed to participate in continued access phase, and use 670G 4.0 system with GS3 and 780G system with Guardian 4 Sensor (G4S).","This multicenter open-label single-arm trial enrolled adolescents (14-21 years) and adults (22-75 years) with type 1 diabetes to evaluate the MiniMed advanced hybrid closed-loop (AHCL) system. The study consisted of two phases: a baseline run-in period (Visits 1-4, approximately 14 days) and a study phase (Visits 5-18, approximately 90 days). During the run-in period, participants used sensor-augmented pump therapy with or without predictive low glucose management or automated basal insulin delivery (Auto Basal), but without automated bolus correction (Auto Correction). During the study phase, both Auto Basal and Auto Correction were enabled with glucose targets set at 100 or 120 mg/dL for approximately 45 days each. The AHCL system included the MiniMed 670G insulin pump (version 4.0 algorithm) with continuous glucose monitoring (Guardian Sensor [3] and Guardian Link [3] transmitter) and incorporated a meal detection module developed by DreaMed Diabetes. Primary endpoints included safety events and changes in A1C, time in range (TIR, 70-180 mg/dL), and time below range (TBR, <70 mg/dL) from the run-in period to the end of the study phase. Additional endpoints included sensor glucose metrics, coefficient of variation, time spent in hyperglycemic ranges (>180, 250, 300 mg/dL), time spent in hypoglycemic ranges (<50, 54, 70 mg/dL), total daily insulin dose, and basal and bolus insulin delivery. Analyses were performed on daytime (6 AM-12 AM) and nighttime (12 AM-6 AM) periods separately. Subgroup analyses examined the effects of glucose target settings, active insulin time (AIT) settings, and closed-loop exits. The intent-to-treat population included 157 participants who entered the study phase, with 152 completing the study. Over 20,229 days of system use during the study, the AHCL system demonstrated no device-related serious adverse events, no severe hypoglycemia, and no diabetic ketoacidosis during the study phase. Participants spent an average of 94.9% of time in closed loop with only 1.2 exits per week. Compared to the run-in period, A1C decreased from 7.5% to 7.0%, TIR increased from 68.8% to 74.5%, and TBR decreased from 3.3% to 2.3%. The 100 mg/dL glucose target and lower AIT setting (2 hours) further optimized glycemic outcomes without increasing hypoglycemia risk.",True,0.86,success,DetailedDescription,protocolSection.descriptionModule.detailedDescription,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.conditionsModule.conditions,TP,TP,['Type 1 Diabetes Mellitus'],"['Type 1 Diabetes Mellitus', 'Diabetes Mellitus, Type 1']",True,1.0,superset,Condition,protocolSection.conditionsModule.conditions,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.conditionsModule.keywords,EV,EV,,"['Advanced hybrid closed-loop system', 'Automated insulin delivery', 'Automated basal insulin', 'Automated bolus correction', 'Continuous glucose monitoring', 'Insulin pump therapy', 'Time in range', 'Hemoglobin A1C', 'Hypoglycemia', 'Hyperglycemia', 'Adolescents', 'Adults', 'MiniMed 670G', 'Sensor-augmented pump', 'Predictive low glucose management', 'Active insulin time', 'Glucose target']",,,,Keyword,protocolSection.conditionsModule.keywords,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.studyType,TP,TP,INTERVENTIONAL,INTERVENTIONAL,True,1.0,exact,StudyType,protocolSection.designModule.studyType,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.patientRegistry,EV,EV,,False,,,,PatientRegistry,protocolSection.designModule.patientRegistry,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.phases,TP,TP,['NA'],['NA'],True,1.0,exact,Phase,protocolSection.designModule.phases,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.allocation,TP,TP,NA,NA,True,1.0,exact,DesignAllocation,protocolSection.designModule.designInfo.allocation,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.interventionModel,TP,TP,SINGLE_GROUP,SINGLE_GROUP,True,1.0,exact,DesignInterventionModel,protocolSection.designModule.designInfo.interventionModel,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.interventionModelDescription,EV,EV,,"This multicenter open-label single-arm study enrolled adolescents (14–21 years of age) and adults (22–75 years of age) with type 1 diabetes. Participants underwent a baseline run-in period comprising Visits 1–4, followed by a study phase comprising Visits 5–18. During the run-in period, participants used the AHCL study device with SAP with or without PLGM or Auto Basal use for approximately 14 days. During the study phase, Auto Basal and Auto Correction were enabled for approximately 90 days, with glucose target set to 100 or 120 mg/dL for approximately 45 days each.",,,,DesignInterventionModelDescription,protocolSection.designModule.designInfo.interventionModelDescription,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.maskingInfo.masking,TP,TP,NONE,NONE,True,1.0,exact,DesignMasking,protocolSection.designModule.designInfo.maskingInfo.masking,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,EV,EV,,This was an open-label single-arm study with no masking.,,,,DesignMaskingDescription,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.enrollmentInfo.count,TP,FP,288,180,False,0.2,success,EnrollmentCount,protocolSection.designModule.enrollmentInfo.count,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[2].label,EV,EV,,Study Phase - 120 mg/dL Target (Visits 5-11 or 12-18),,,,ArmGroupLabel,protocolSection.armsInterventionsModule.armGroups.label,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[2].type,EV,EV,,EXPERIMENTAL,,,,ArmGroupType,protocolSection.armsInterventionsModule.armGroups.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[2].description,EV,EV,,Participants used the MiniMed AHCL system with both Auto Basal and Auto Correction enabled with a glucose target of 120 mg/dL for approximately 45 days. This could be the first or second half of the study phase depending on randomization.,,,,ArmGroupDescription,protocolSection.armsInterventionsModule.armGroups.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[2].interventionNames,EV,EV,,['DEVICE: MiniMed AHCL System - Auto Basal + Auto Correction (120 mg/dL)'],,,,ArmGroupInterventionName,protocolSection.armsInterventionsModule.armGroups.interventionNames,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[1].type,EV,EV,,DEVICE,,,,InterventionType,protocolSection.armsInterventionsModule.interventions.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[1].name,EV,EV,,MiniMed AHCL System - Auto Basal + Auto Correction (100 mg/dL),,,,InterventionName,protocolSection.armsInterventionsModule.interventions.name,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[1].description,EV,EV,,"The MiniMed AHCL system with automated basal insulin delivery (Auto Basal) and automated bolus correction (Auto Correction) every 5 minutes, with glucose target set to 100 mg/dL. The system includes the MiniMed 670G insulin pump (version 4.0 algorithm) with CGM system and a meal detection module developed by DreaMed Diabetes.",,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[1].armGroupLabels,EV,EV,,['Study Phase - 100 mg/dL Target (Visits 5-11 or 12-18)'],,,,InterventionArmGroupLabel,protocolSection.armsInterventionsModule.interventions.armGroupLabels,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[10].measure,EV,EV,,Total bolus insulin delivered,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[11].measure,EV,EV,,Automated correction insulin delivery,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[12].measure,EV,EV,,Percentage of time spent in closed loop,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[13].measure,EV,EV,,Number of closed loop exits,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[3].measure,EV,EV,,Change in time below range (TBR) at <54 mg/dL,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[5].measure,EV,EV,,Change in time above range (TAR) at >180 mg/dL,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[7].measure,EV,EV,,Change in time above range (TAR) at >300 mg/dL,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[8].measure,EV,EV,,Total daily dose of insulin (TDD),,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[9].measure,EV,EV,,Total basal insulin delivered,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[10].description,EV,EV,,"Total bolus insulin (in units) delivered per period, including user-initiated and automated correction boluses",,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[11].description,EV,EV,,"Automated correction insulin (in units) delivered per period, also measured as a percentage of total bolus insulin",,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[12].description,EV,EV,,Percentage of time the advanced hybrid closed-loop (AHCL) system was active in closed-loop mode during the study phase,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[13].description,EV,EV,,Number of unplanned exits from closed-loop mode per participant per week during the study phase,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[3].description,EV,EV,,Percentage of time spent below glucose range at <54 mg/dL measured by CGM from the end of the run-in period to the end of the study phase,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[5].description,EV,EV,,Percentage of time spent above glucose range at >180 mg/dL measured by CGM from the end of the run-in period to the end of the study phase,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[7].description,EV,EV,,Percentage of time spent above glucose range at >300 mg/dL measured by CGM from the end of the run-in period to the end of the study phase,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[8].description,EV,EV,,"Total insulin (in units) delivered per day or per period, including basal, bolus, and automated correction insulin",,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[9].description,EV,EV,,Total basal (basal + microbolus) insulin (in units) delivered per period,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[10].timeFrame,EV,EV,,During study phase (~90 days),,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[11].timeFrame,EV,EV,,During study phase (~90 days),,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[12].timeFrame,EV,EV,,During study phase (~90 days),,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[13].timeFrame,EV,EV,,During study phase (~90 days),,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[3].timeFrame,EV,EV,,From end of run-in period (~14 days) to end of study phase (~90 days),,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[5].timeFrame,EV,EV,,From end of run-in period (~14 days) to end of study phase (~90 days),,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[7].timeFrame,EV,EV,,From end of run-in period (~14 days) to end of study phase (~90 days),,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[8].timeFrame,EV,EV,,During study phase (~90 days),,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[9].timeFrame,EV,EV,,During study phase (~90 days),,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[0].measure,EV,EV,,Safety events: Severe hypoglycemia,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[10].measure,EV,EV,,Daytime and nighttime glycemic outcomes,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[1].measure,EV,EV,,Safety events: Diabetic ketoacidosis (DKA),,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[2].measure,EV,EV,,Safety events: Serious adverse events (SAEs),,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[3].measure,EV,EV,,Safety events: Serious adverse device effects (SADEs),,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[4].measure,EV,EV,,Safety events: Unanticipated adverse device effects,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[5].measure,EV,EV,,Proportion of participants achieving A1C <7%,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[6].measure,EV,EV,,Proportion of participants achieving TIR >70%,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[7].measure,EV,EV,,"Composite outcome: TIR >70%, TBR <70 mg/dL <4%, and TBR <54 mg/dL <1%",,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[8].measure,EV,EV,,Subgroup analysis by glucose target setting (100 mg/dL vs. 120 mg/dL),,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[9].measure,EV,EV,,Subgroup analysis by active insulin time (AIT) setting,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[0].description,EV,EV,,Incidence of severe hypoglycemia during the run-in period and study phase,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[10].description,EV,EV,,"Glycemic outcomes (TIR, TBR, TAR, mean SG, CV of SG) analyzed separately for daytime (6 AM–12 AM) and nighttime (12 AM–6 AM) periods",,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[1].description,EV,EV,,Incidence of diabetic ketoacidosis (DKA) during the run-in period and study phase,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[2].description,EV,EV,,Incidence of serious adverse events during the run-in period and study phase,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[3].description,EV,EV,,Incidence of serious adverse device effects during the run-in period and study phase,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[4].description,EV,EV,,Incidence of unanticipated adverse device effects during the run-in period and study phase,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[5].description,EV,EV,,Percentage of participants achieving the recommended hemoglobin A1C goal of <7% at the end of the study phase,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[6].description,EV,EV,,Percentage of participants achieving the recommended time in range (TIR) goal of >70% at the end of the study phase,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[7].description,EV,EV,,"Percentage of participants achieving the composite of TIR >70%, TBR <70 mg/dL <4%, and TBR <54 mg/dL <1% at the end of the study phase",,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[8].description,EV,EV,,"Effect of glucose target setting (100 mg/dL vs. 120 mg/dL) on glycemic outcomes (TIR, TBR, TAR, mean SG) during the study phase",,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[9].description,EV,EV,,"Association between active insulin time (AIT) setting and glycemic outcomes (TIR, TBR) during the study phase",,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[0].timeFrame,EV,EV,,From start of run-in period (~14 days) through end of study phase (~90 days),,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[10].timeFrame,EV,EV,,From end of run-in period (~14 days) to end of study phase (~90 days),,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[1].timeFrame,EV,EV,,From start of run-in period (~14 days) through end of study phase (~90 days),,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[2].timeFrame,EV,EV,,From start of run-in period (~14 days) through end of study phase (~90 days),,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[3].timeFrame,EV,EV,,From start of run-in period (~14 days) through end of study phase (~90 days),,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[4].timeFrame,EV,EV,,From start of run-in period (~14 days) through end of study phase (~90 days),,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[5].timeFrame,EV,EV,,End of study phase (~90 days),,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[6].timeFrame,EV,EV,,End of study phase (~90 days),,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[7].timeFrame,EV,EV,,End of study phase (~90 days),,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[8].timeFrame,EV,EV,,"During study phase (~90 days, with ~45 days per target setting)",,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[9].timeFrame,EV,EV,,During study phase (~90 days),,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.eligibilityCriteria,TP,TP,"Inclusion Criteria:

1. Subject is age 7-75 years at time of Screening
2. Subjects 14-75 years of age: A clinical diagnosis of type 1 diabetes for 2 years or more as determined via medical record or source documentation by an individual qualified to make a medical diagnosis
3. Subjects 7-13 years of age: A clinical diagnosis of type 1 diabetes for 1 year or more as determined via medical record or source documentation by an individual qualified to make a medical diagnosis Study-specific inclusion criteria
4. Subject is willing to perform ≥ 4 finger stick blood glucose measurements daily
5. Subject is willing to perform required sensor calibrations
6. Subject is willing to wear the system continuously throughout the study
7. Subject must have a minimum daily insulin requirement (Total Daily Dose) of greater than or equal to 8 units
8. Subject has a Glycosylated hemoglobin (HbA1c) less than 10% (as processed by Central Lab) at time of Screening visit Note: All HbA1c blood specimens will be sent to and tested by a NGSP certified Central Laboratory. HbA1c testing must follow National Glycohemoglobin Standardization Program (NGSP) standards.
9. Subject has TSH in the normal range OR if the TSH is out of normal reference range the Free T3 is below or within the lab's reference range and Free T4 is within the normal reference range.
10. Pump therapy for greater than 6 months prior to screening (with or without CGM experience)
11. Subject must have a companion or caregiver available at night for the duration of the study period who resides (or will live) in in the same building (or home). A companion or caregiver should also be available during exercise challenges in the same building, home or location (if not at home). This requirement may be verified by subject report at screening visit.
12. Subject willing to upload data from the study pump, must have Internet access and a computer system that meets the requirements for uploading the study pump
13. If subject has celiac disease, it has been adequately treated as determined by the investigator
14. Subject is willing to take one of the following insulins and can financially support the use of either of the 2 insulin preparations throughout the course of the study (i.e. co-payments for insulin with insurance or able to pay full amount)

    * Humalog™\* (insulin lispro injection)
    * NovoLog™\* (insulin aspart)
15. Subjects with history of cardiovascular event 1 year or more from the time of screening must have an EKG within 6 months prior to screening or during screening. If subject has an abnormal EKG, participation is allowed if there is clearance from a cardiologist
16. Subjects with the 3 or more cardiovascular risk factors listed below must have an EKG within 6 months prior to screening or during screening. If subject has an abnormal EKG, participation is allowed if there is clearance from a cardiologist

    a. Cardiovascular risk factors include:
    * Age \>35 years
    * Type 1 diabetes of \>15 years' duration
    * Presence of any additional risk factor for coronary artery disease
    * Presence of microvascular disease (proliferative retinopathy or nephropathy, including microalbuminuria)
    * Presence of peripheral vascular disease
    * Presence of autonomic neuropathy
17. Subjects with history of cardiovascular event 1 year or more from the time of screening must have a stress test within 6 months prior to screening or during run in period. If subject fails stress test, participation is allowed if there is clearance from a cardiologist

Exclusion Criteria:

1. Subject has a history of 1 or more episodes of severe hypoglycemia, which resulted in any the following during the 6 months prior to Screening:

   1. Medical assistance (i.e. Paramedics, Emergency Room (ER) or Hospitalization)
   2. Coma
   3. Seizures
2. Subject has been hospitalized or has visited the ER in the 6 months prior to Screening resulting in a primary diagnosis of uncontrolled diabetes
3. Subject has had Diabetic Ketoacidosis (DKA) in the 6 months prior to Screening.
4. Subject has Hypoglycemia Unawareness, as measured by the Gold questionnaire (Gold, MacLeod et al. 1994) at Screening
5. Subject is unable to tolerate tape adhesive in the area of sensor placement
6. Subject has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection)
7. Women of child-bearing potential who have a positive pregnancy test at Screening or plan to become pregnant during the course of the study
8. Females who are sexually active and able to conceive will be excluded if they are not using an effective method of contraception and do not agree to continue using an effective method of contraception for the duration of the study as determined by investigator.
9. Subject has had any of the following cardiovascular events within 1 year of screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease
10. Subject is being treated for hyperthyroidism at time of Screening
11. Subject has a diagnosis of adrenal insufficiency
12. Subject has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8 weeks from time of Screening, or plans to take any oral, injectable, or IV glucocorticoids during the course of the study
13. Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks
14. Subject is currently abusing illicit drugs
15. Subject is currently abusing marijuana
16. Subject is currently abusing prescription drugs
17. Subject is currently abusing alcohol
18. Subject is using pramlintide (Symlin), DPP-4 inhibitor, liraglutide (Victoza or other GLP-1 agonists), metformin, canagliflozin (Invokana or other SGLT2 inhibitors) at time of Screening
19. Subject has a history of visual impairment which would not allow subject to participate in the study and perform all study procedures safely, as determined by the investigator
20. Subject has elective surgery planned that requires general anesthesia during the course of the study
21. Subject has a sickle cell disease, hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of Screening
22. Subject plans to receive red blood cell transfusion or erythropoietin over the course of study participation
23. Subject diagnosed with current eating disorder such as anorexia or bulimia
24. Subject has been diagnosed with chronic kidney disease that results in chronic anemia
25. Subject has a hematocrit that is below the normal reference range of lab used.
26. Subject is on dialysis
27. Subject has serum creatinine of \>2 mg/dL.
28. Research staff involved with the study.","**Inclusion Criteria:**
- Diagnosis of type 1 diabetes (T1D) at screening
- Duration of T1D for at least 2 years
- Minimum daily insulin requirement of at least 8 units
- Hemoglobin A1C of <10% at screening
- Use of pump therapy with or without CGM experience for >6 months before screening
- Willingness to wear the system throughout the study and perform at least four daily self-monitoring of blood glucose measurements and required sensor calibrations
- Ability to upload data from the study device to the CareLink™ clinical software
- A caregiver available at night who resided (or lived) in the same building (or home), during the study

**Exclusion Criteria:**
- History of one or more episodes of severe hypoglycemia that resulted in a coma, seizure, or hospitalization during the 6 months before screening
- Hospitalization or emergency room visit resulting in a primary diagnosis of uncontrolled diabetes in the 6 months before screening
- Diabetic ketoacidosis (DKA) in the 6 months before screening
- Hypoglycemia unawareness, as measured by the Gold questionnaire at screening
- Inability to tolerate tape adhesive in the area of sensor placement or an unresolved adverse skin condition (e.g., psoriasis, dermatitis herpetiformis, rash, or staphylococcus infection) in the area of sensor placement",True,0.96,success,EligibilityCriteria,protocolSection.eligibilityModule.eligibilityCriteria,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.healthyVolunteers,TP,TP,False,False,True,1.0,exact,HealthyVolunteers,protocolSection.eligibilityModule.healthyVolunteers,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.sex,TP,TP,ALL,ALL,True,1.0,exact,Sex,protocolSection.eligibilityModule.sex,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.minimumAge,TP,TP,7 Years,14 Years,True,0.7,success,MinimumAge,protocolSection.eligibilityModule.minimumAge,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.maximumAge,TP,TP,75 Years,75 Years,True,1.0,exact,MaximumAge,protocolSection.eligibilityModule.maximumAge,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.stdAges,TP,TP,"['CHILD', 'ADULT', 'OLDER_ADULT']","['CHILD', 'ADULT', 'OLDER_ADULT']",True,1.0,exact,StdAge,protocolSection.eligibilityModule.stdAges,False,True,True,False,True,False
